profit from every $100 of sales.
$0$100
Edesa Biotech
$1.94-6.73% today
+12.1% in 1 year
1-year low $0.801-year high $18.28
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Edesa Biotech sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$7.19 million of profit last year.
SalesProfit
Edesa Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Edesa Biotech | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Edesa Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -18 | -9 | -6 | -7 | |
| -17 | -8 | -6 | -7 | |
| -18 | -8 | -6 | -7 | |
| -7.35 | -2.93 | -1.93 | -1.27 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 9 | 4 | 14 |
| Cash | 7 | 5 | 1 | 11 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 2 | 2 | 2 | 1 |
| 9 | 7 | 2 | 12 | |
| 2 | 3 | 3 | 6 | |
| -147.7% | -95.6% | -249.4% | -45.2% | |
| -186.9% | -118.8% | -311.4% | -57.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -12 | -7 | -5 | -7 | |
| 0 | – | – | – | |
| -12 | -7 | -5 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 9.3×
- –
- –
- –
- -27.9%
- -27.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -59.9%
- -154.2%
- -55.8%
- -53.1%
- -59.9%
- –
Growth
- –
- –
- −49.7%
- –
- +34.7%
Financial health
- -1.6×
- 0.00
- 0.0%
- –
- 16.82
- 16.82
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 963
Bottom 20%of 894
Bottom 2%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.49 | -0.24 | −104.2% |
| Feb 13, 2026 | -0.28 | -0.28 | +0.0% |
| Dec 12, 2025 | -0.32 | -0.27 | −18.5% |
| Aug 8, 2025 | -0.25 | -0.26 | +3.8% |
| May 14, 2025 | -0.30 | -0.30 | +0.0% |
| Feb 14, 2025 | -0.48 | -0.31 | −54.8% |
| Dec 13, 2024 | -0.29 | -0.54 | +46.3% |
| Aug 9, 2024 | -0.52 | -0.58 | +10.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
40No pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
32No pass
Questions about Edesa Biotech
Is Edesa Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Edesa Biotech AI analysis
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. It is in Biotechnology.
Does Edesa Biotech pay a dividend?
No. Edesa Biotech does not pay a dividend at the moment.
Is Edesa Biotech stock halal?
No. Edesa Biotech does not pass our halal screen: its cash and confirmed interest-bearing investments are 41% of its market value, at or above the 33% limit. How we check
How has Edesa Biotech stock done over the past year?
Up 12.1% over the past twelve months, to $1.94. It traded between $0.80 and $18.28 and is 89.4% below its high.
Who are Edesa Biotech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Edesa Biotech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.